All In Biotech

Drug Trial Radar · NCT07929493

A Study of Ceftobiprole Compared With Standard Antibiotic Treatment in Children With Staphylococcus Aureus Bacteremia (SAB) Infection, Including Right-sided Heart Infection

A Multicenter, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftobiprole Versus Standard-of-care Treatment in Pediatric Patients From Birth to Less Than 18 Years With Staphylococcus Aureus Bacteremia, Including Right-sided Infective Endocarditis

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Oct 31, 2028

Study completion Oct 31, 2028

Sponsor

Lead sponsor
ISTx, LLCIndustry
Sponsor type
Industry
Collaborators
Innoviva Specialty Therapeutics
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 days, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial will evaluate the safety, and effectiveness of ceftobiprole compared to standard-of-care antibiotic treatment in children from birth to less than 18 years of age with Staphylococcus aureus bloodstream infection, including right-sided infective endocarditis (IE). The trial will also evaluate the pharmacokinetics of ceftobiprole.

Conditions

  • Staphylococcus Aureus Bacteremia
  • Endocarditis, Bacterial

Interventions

  • Ceftobiprole medocaril sodiumDrug

    Ceftobiprole dosing is based on age/body weight and renal function and given at 7.5 mg/kg, 10 mg/kg, or 15 mg/kg (equivalent to 10 mg/kg, 13.3 mg/kg, or 20 mg/kg respectively of ceftobiprole medocaril sodium) q8h, q12h or q24h up to a maximum of 500 mg (equivalent to 667 mg of ceftobiprole medocaril sodium), with all doses infused over 2 hours.

  • Standard of Care (SOC)Drug

    Dosage is per local product label based on the participant's age/body weight, and, if applicable, renal function.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 through last follow-up (LFU) [up to 11 weeks]
  2. Percentage of participants with serious adverse events (SAEs)Time frame: Baseline through LFU [up to 11 weeks]
  3. Percentage of participants with treatment-related adverse events (AEs)Time frame: Day 1 through LFU [up to 11 weeks]
  4. Percentage of participants with adverse events of special interest (AESIs)Time frame: Baseline through LFU [up to 11 weeks]
  5. Percentage of participants with adverse events (AEs) leading to discontinuation of study-drug treatmentTime frame: Baseline through LFU [up to 11 weeks]
  6. Percentage of participants with treatment-emergent abnormal hematology laboratory test resultsTime frame: Baseline through the end-of-treatment (EOT) visit [up to approximately 6 weeks]
  7. Percentage of participants with treatment-emergent abnormal blood chemistry laboratory test resultsTime frame: Baseline through the EOT visit [up to approximately 6 weeks]
  8. Percentage of participants with treatment-emergent abnormal urinalysis test resultsTime frame: Baseline through the EOT visit [up to approximately 6 weeks]
  9. Change from baseline in body temperatureTime frame: Baseline through LFU visit [up to 11 weeks]
  10. Change from baseline in systolic blood pressureTime frame: Baseline through LFU visit [up to 11 weeks]
  11. Change from baseline in diastolic blood pressureTime frame: Baseline through LFU visit [up to 11 weeks]
  12. Change from baseline in respiratory rateTime frame: Baseline through LFU visit [up to 11 weeks]
  13. Change from baseline in heart rateTime frame: Baseline through LFU visit [up to 11 weeks]

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.